PipelineReview. Business Intellegence Center

All News

5 June 2012

Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate CancerAntibodies

5 June 2012

ThromboGenics and BioInvent To Regain Full Rights to TB-403Antibodies

5 June 2012

ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402Antibodies

4 June 2012

ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast CancerAntibodies

4 June 2012

ImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419Antibodies

3 June 2012

Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus ChemotherapyAntibodies

3 June 2012

Genentech’s Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III TrialAntibodies

2 June 2012

Genentech Study Showed That Adding Avastin to Chemotherapy Cut the Risk of the Disease Getting Worse in Difficult-to-Treat Recurrent Ovarian Cancer by HalfAntibodies

2 June 2012

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell CancerAntibodies

28 May 2012

Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The LancetAntibodies

24 May 2012

Celldex’s CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated Levels of GPNMB and in Triple Negative DiseaseAntibodies

23 May 2012

AVEO Initiates Phase 1 Study of AV-203, an ERBB3 Inhibitory Antibody, in Advanced Solid TumorsAntibodies

22 May 2012

New Phase 3 Study Results Show Anti-Tnf Simponi® Induced Clinical Response in Adults with Moderately to Severely Active Ulcerative ColitisAntibodies

22 May 2012

MorphoSys and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial in CLLAntibodies

21 May 2012

iPierian Advances Monoclonal Antibody Drug Development Programs Targeting Tau Protein and the Complement System for the Treatment of Neurodegenerative DiseasesAntibodies

21 May 2012

Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung CancerAntibodies

18 May 2012

New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of MedicineAntibodies

17 May 2012

Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd)Antibodies

17 May 2012

Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal CancerAntibodies

17 May 2012

Amgen’s BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaAntibodies

16 May 2012

Amorfix Announces the Development of Antibodies that Bind to Misfolded Fas Receptor Protein as a Potential Treatment for CancerAntibodies

15 May 2012

Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza AAntibodies

15 May 2012

TG Therapeutics, Inc. Announces Investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S.Antibodies

15 May 2012

Helix BioPharma Corp. Commences Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47Antibodies

11 May 2012

Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance PhasesAntibodies

11 May 2012

Cell Signaling Technology, Inc. Develops Novel Monoclonal Antibody Discovery PlatformAntibodies

10 May 2012

Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell LymphomaAntibodies

9 May 2012

Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit at Pre-specified Interim AnalysisAntibodies

9 May 2012

Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST (rilonacept) InjectionAntibodies

9 May 2012

Thallion and LFB Report Positive Top-Line Results from the Phase II SHIGATEC Trial at ‘VTEC 2012’Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins
GPC3-Targeted Immunotherapy Pipeline Review
CCR8-Targeted Antibody Immunotherapy Pipeline Review
Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective
Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins
Report Package: Bispecific Antibodies
2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
FcRn Inhibitors Pipeline Review